Page 32 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine FAP-targeted RLT in cancer

23. Wang LCS, Lo A, Scholler J, et al., 2014, Targeting fibroblast Samarium-labeled FAPI-46 radioligand therapy in a patient
activation protein in tumor stroma with chimeric antigen receptor with lung metastases of a sarcoma. Eur J Nucl Med Mol
T cells can inhibit tumor growth and augment host immunity Imaging, 48: 3011–3013.
without severe toxicity. Cancer Immunol Res, 2: 154–166.
https://doi.org/10.1007/s00259-021-05273-8
https://doi.org/10.1158/2326-6066.CIR-13-0027
34. Fu K, Pang Y, Zhao L, et al., 2022, FAP-targeted
24. Laklai H, Miroshnikova YA, Pickup MW, et al., 2016, radionuclide therapy with [ Lu]Lu-FAPI-46 in metastatic
177
Genotype tunes pancreatic ductal adenocarcinoma nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging,
tissue tension to induce matricellular fibrosis and tumor 49: 1767–1769.
progression. Nat Med, 22: 497–505.
https://doi.org/10.1007/s00259-021-05634-3
https://doi.org/10.1038/nm.4082
35. Zhao L, Niu B, Fang J, et al., 2022, Synthesis, preclinical
25. Valkenburg KC, de Groot AE, Pienta KJ, 2018, Targeting evaluation, and a pilot clinical PET imaging study of
the tumour stroma to improve cancer therapy. Nat Rev Clin 68 Ga-Labeled FAPI dimer. J Nucl Med, 63: 862–868.
Oncol, 15: 366–381.
https://doi.org/10.2967/jnumed.121.263016
https://doi.org/10.1038/s41571-018-0007-1
36. Pang Y, Zhao L, Fang J, et al., 2023, Development of FAPI
26. Kessler L, Ferdinandus J, Hirmas N, et al., 2022, Pitfalls and tetramers to improve tumor uptake and efficacy of FAPI
common findings in Ga-FAPI PET: A pictorial analysis. radioligand therapy. J Nucl Med, 64: 1449–1455.
68
J Nucl Med, 63: 890–896.
https://doi.org/10.2967/jnumed.123.265599
https://doi.org/10.2967/jnumed.121.262808
37. Zhao L, Chen J, Pang Y, et al., 2022, Development of fibroblast
27. van den Hoven AF, Keijsers RGM, Lam M, et al., 2023, activation protein inhibitor-based dimeric radiotracers with
Current research topics in FAPI theranostics: A bibliometric improved tumor retention and antitumor efficacy. Mol
analysis. Eur J Nucl Med Mol Imaging, 50: 1014–1027. Pharm, 19: 364036-51.
https://doi.org/10.1007/s00259-022-06052-9 https://doi.org/10.1021/acs.molpharmaceut.2c00424
28. Pang Y, Zhao L, Meng T, et al., 2023, PET imaging of 38. Moon ES, Ballal S, Yadav MP, et al., 2021, Fibroblast activation
fibroblast activation protein in various types of cancer protein (FAP) targeting homodimeric FAP inhibitor
using 68 Ga-FAP-2286: Comparison with 18 F-FDG and radiotheranostics: A step to improve tumor uptake and
68 Ga-FAPI-46 in a single-center, prospective study. J Nucl retention time. Am J Nucl Med Mol Imaging, 11: 476–491.
Med, 64: 386–394.
39. Zboralski D, Hoehne A, Bredenbeck A, et al., 2022,
https://doi.org/10.2967/jnumed.122.264544 Preclinical evaluation of FAP-2286 for fibroblast activation
29. Polson AG, Fuji RN, 2012, The successes and limitations of protein targeted radionuclide imaging and therapy. Eur J
preclinical studies in predicting the pharmacodynamics and Nucl Med Mol Imaging, 49: 3651–3667.
safety of cell-surface-targeted biological agents in patients. https://doi.org/10.1007/s00259-022-05842-5
Br J Pharmacol, 166: 1600–1602.
40. Wen X, Xu P, Shi M, et al., 2022, Evans blue-modified
https://doi.org/10.1111/j.1476-5381.2012.01916.x radiolabeled fibroblast activation protein inhibitor as long-
30. Watabe T, Liu Y, Kaneda-Nakashima K, et al., 2020, acting cancer therapeutics. Theranostics, 12: 422–433.
Theranostics targeting fibroblast activation protein in the https://doi.org/10.7150/thno.68182
tumor stroma: Cu- and Ac-labeled FAPI-04 in pancreatic
64
225
cancer xenograft mouse models. J Nucl Med, 61: 563–569. 41. Xu M, Zhang P, Ding J, et al., 2022, Albumin binder-
conjugated fibroblast activation protein inhibitor
https://doi.org/10.2967/jnumed.119.233122 radiopharmaceuticals for cancer therapy. J Nucl Med,
31. Loktev A, Lindner T, Burger EM, et al., 2019, Development 63: 952–958.
of fibroblast activation protein-targeted radiotracers with https://doi.org/10.2967/jnumed.121.262533
improved tumor retention. J Nucl Med, 60: 1421–1429.
42. Tranel J, Palm S, Graves SA, et al., 2022, Impact of
https://doi.org/10.2967/jnumed.118.224469 radiopharmaceutical therapy ( Lu, Ac) microdistribution
225
177
32. Rathke H, Fuxius S, Giesel FL, et al., 2021, Two tumors, one in a cancer-associated fibroblasts model. EJNMMI Phys,
target: Preliminary experience with 90Y-FAPI therapy in a 9: 67.
patient with metastasized breast and colorectal cancer. Clin https://doi.org/10.1186/s40658-022-00497-5
Nucl Med, 46: 842–844.
43. Jokar N, Velikyan I, Ahmadzadehfar H, et al., 2021,
https://doi.org/10.1097/RLU.0000000000003842.
Theranostic approach in breast cancer: A treasured tailor for
33. Kratochwil C, Giesel FL, Rathke H, et al., 2021, [ Sm] future oncology. Clin Nucl Med, 46: e410–e420.
153

Volume 1 Issue 2 (2023) 11 https://doi.org/10.36922/arnm.1667